
Please try another search
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 which is in preclinical trial to treat metabolic dysfunction-associated steatohepatitis; ETX-407 which is in preclinical trial for the treatment of dry age-related macular degeneration; and ETX-148 which is in preclinical trial for the treatment of bleeding disorders. In addition, the company develops ETX-291 which is in preclinical trial to treat cardiometabolic disease; and ETX-258 which is in preclinical trial for heart failure treatment. e-therapeutics plc was incorporated in 2001 and is based in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Bill Harte | - | 2020 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review